Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/80594
PIRA download icon_1.1View/Download Full Text
Title: Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation
Authors: Li, XX 
Lu, XY
Zhang, SJ 
Chiu, AP 
Lo, LH 
Largaespada, DA
Chen, QB
Keng, VW 
Issue Date: Mar-2019
Source: Biomedicine and pharmacotherapy, Mar. 2019, v. 111, p. 68-75
Abstract: Non-alcoholic fatty liver disease (NAFLD) is becoming an epidemic disease in adults and children worldwide. Importantly, there are currently no approved treatments available for NAFLD. This study aims to investigate the potential applications of sodium tanshinone IIA sulfonate (STS) on improving the NAFLD condition using both in vitro and in vivo approaches. The results showed that STS markedly inhibited lipid accumulation in oleic acid (OA) and palmitic acid (PA) treated HepG2 and primary immortalized human hepatic (PIH) cells. STS suppressed lipogenesis by inhibiting expression of sterol regulatory element binding transcription factor 1 (SREBF1), fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). In addition, STS reduced inflammation in cells treated with OA-PA, shown by decreased transcriptional levels of tumor necrosis factor (TNF), transforming growth factor beta 1 (TGFB1) and interleukin 1 beta (IL1B). Consistently, protective effects on hepatic steatosis in db/db mice were observed after STS administration, demonstrated by decreased lipid accumulation in mouse hepatocytes. This protective effect might be associated with STS induced activation of sirtuin 1 (SIRT1)/protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1) pathways. Our findings suggest a potential therapeutic role for STS in the treatment of NAFLD.
Keywords: NAFLD
PRKAA1
SIRT1
Sodium tanshinone IIA sulfonate
Publisher: Elsevier Masson
Journal: Biomedicine and pharmacotherapy 
EISSN: 0753-3322
DOI: 10.1016/j.biopha.2018.12.019
Rights: © 2018 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
The following publication: Li, X. X., Lu, X. Y., Zhang, S. J., Chiu, A. P., Lo, L. H., Largaespada, D. A., ... & Keng, V. W. (2019). Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomedicine & Pharmacotherapy, 111, 68-75 is available at https://doi.org/10.1016/j.biopha.2018.12.019
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Li_Sodium_tanshinone_IIA.pdf2.88 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show full item record

Page views

108
Citations as of May 15, 2022

Downloads

130
Citations as of May 15, 2022

SCOPUSTM   
Citations

18
Citations as of May 20, 2022

WEB OF SCIENCETM
Citations

17
Citations as of May 19, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.